The method is based on three steps:
A. Substances assessed as endocrine disruptors as defined by the EU *
B. Substances that are listed on three selected lists and where there are indications that the substances are endocrine disruptors or alternatively that they are being investigated within the EU.
C. The possibility of questioning the substances listed under B if there are scientifically robust arguments. Mandatory documentation requirements and approval process.
Figure 1. Decision tree for the management of endocrine disruptors.
In cases where step C becomes relevant, the documentation must contain:
• A summary that clarifies the substance, CAS number, in which construction products the substance is included and reasons why the substance should not be considered endocrine disruptor. Basta reserves the right to publish this summary on Basta’s website.
• A justification that addresses all arguments as to why the topic is included in one or more of the lists in step B and why these arguments are considered incorrect.
• Scientific evidence, including references to literature studies and tests, when reference is made to studies
The documentation shall be sent to: Bastaonline AB, Box 210 60, 100 31 Stockholm or via email to bastaonline@ivl.se.Basta uses expert support for evaluation of the documentation, and the cost of the evaluation is paid by the applicant – Basta provides price information on request. When requested, the substance (CAS number and chemical name), which building products the substance is included in, as well as the organization number and invoice address shall be included.